$-1.06 EPS Expected for Adamas Pharmaceuticals Inc (ADMS)

October 14, 2017 - By Louis Casey

 $ 1.06 EPS Expected for Adamas Pharmaceuticals Inc (ADMS)

Analysts await Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report earnings on November, 2. They expect $-1.06 EPS, down 60.61 % or $0.40 from last year’s $-0.66 per share. After $-0.93 actual EPS reported by Adamas Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 13.98 % negative EPS growth. The stock decreased 4.13% or $0.82 during the last trading session, reaching $19.02. About 841,165 shares traded. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 0.40% since October 14, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Among 9 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 8 have Buy rating, 1 Sell and 0 Hold. Therefore 89% are positive. Adamas Pharmaceuticals had 22 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) earned “Neutral” rating by Mizuho on Tuesday, January 19. The stock has “Buy” rating by Zacks on Friday, August 7. Piper Jaffray maintained Adamas Pharmaceuticals Inc (NASDAQ:ADMS) on Tuesday, October 3 with “Buy” rating. The stock has “Market Outperform” rating by JMP Securities on Friday, August 25. Noble Financial maintained Adamas Pharmaceuticals Inc (NASDAQ:ADMS) on Wednesday, August 9 with “Buy” rating. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has “Buy” rating given on Friday, September 15 by Needham. The firm earned “Outperform” rating on Thursday, December 24 by Credit Suisse. The firm earned “Buy” rating on Wednesday, August 9 by Cowen & Co. The firm has “Buy” rating by Mizuho given on Friday, August 25. On Tuesday, January 19 the stock rating was initiated by Cowen & Co with “Outperform”.

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $428.22 million. The Firm is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It currently has negative earnings. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

More notable recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Seekingalpha.com which released: “Adamas Prepares For Parkinson’s Launch” on September 14, 2017, also Seekingalpha.com with their article: “Adamas Releases Pricing For GOCOVRI” published on September 20, 2017, Nasdaq.com published: “Adamas Announces New Employment Inducement Grant” on October 06, 2017. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were released by: Streetinsider.com and their article: “Adamas Pharma (ADMS) Names Mardi Dier to Board” published on October 11, 2017 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare coverage changes” with publication date: September 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com